Dermatosis ampollosas

  1. Ballester Martínez, M.A. 1
  2. Jaén Olasolo, P. 1
  1. 1 Servicio de Dermatología. Hospital Universitario Ramón y Cajal. Madrid. España
Revue:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Année de publication: 2022

Titre de la publication: Enfermedades de la piel (II)

Serie: 13

Número: 48

Pages: 2800-2809

Type: Article

DOI: 10.1016/J.MED.2022.02.003 DIALNET GOOGLE SCHOLAR

D'autres publications dans: Medicine: Programa de Formación Médica Continuada Acreditado

Résumé

Autoimmune blistering diseases (ABD) are a heterogeneous group of diseases characterized by the presence of autoantibodies against various structures involved in the cellular cohesion of the skin. The depositing of these autoantibodies produces the histological finding that is common to all ABDs: acantholysis, which can be intraepidermal, as occurs in the pemphigus group, or subepidermal, as in pemphigoids. ABDs progress clinically with vesicles, blisters, or erosions in both the skin and the mucus membranes. Symptoms vary according to each disease. For diagnosis, conducting a skin biopsy is essential both for a conventional histological study and for confirmation of the presence of autoantibodies, which can be determined through visualization of deposits in the tissue (direct immunofluorescence) or of circulating antibodies (serological studies). Management of ABDs is based on the use of glucocorticoids and/or immunosuppressive drugs, monoclonal antibodies such as rituximab, or other drugs such as dapsone or immunoglobulins. Without treatment, these diseases can entail significant morbidity and mortality. Therefore, appropriate follow-up on patients, preferably in a multidisciplinary context, is necessary.

Références bibliographiques

  • Di Lernia V, Casanova DM, Goldust M, Ricci C. Pemphigus vulgaris and bullous pemphigoid: update on diagnosis and treatment. Dermatol Pract Concept. 2020;10(3):e2020050.
  • Tavakolpour S. Pemphigus trigger factors: special focus on pemphigus vulgaris and pemphigus foliaceus. Arch Dermatol Res. 2018;310(2):95-106.
  • Olbrich M, Künstner A, Witte M, Busch H, Fähnrich A. Genetics and omics analysis of autoimmune skin blistering diseases. Front Immunol. 2019;10:2327.
  • Bagci IS, Horvath ON, Ruzicka T, Sardy M. Bullous pemphigoid. Autoimmun Rev. 2017;16(5):445-55.
  • Verheyden MJ, Bilgic A, Murrell DF. A systematic review of drug-induced pemphigoid. Acta Derm Venereol. 2020;100(15):adv00224.
  • Cohen S, Strowd LC, Pichardo RO. Pemphigoid gestationis: a case series and review of the literature. J Dermatolog Treat. 2018;29(8):815-8.
  • Daniel BS, Murrell DF. Review of autoimmune blistering diseases: the Pemphigoid diseases. J Eur Acad Dermatol Venereol. 2019;33(9):1685-94.
  • Bolotin D, Petronic- osic V. Dermatitis herpetiformis. Part I. Epidemiology, pathogenesis, and clinical presentation. J Am Acad Dermatol. 2011;64(6):1017-24; quiz 1025-6.
  • Genovese G, Venegoni L, Fanoni D, Muratori S, Berti E, Marzano AV. Linear IgA bullous dermatosis in adults and children: a clinical and immunopathological study of 38 patients. Orphanet J Rare Dis. 2019;14(1):115.
  • Kridin K, Kneiber D, Kowalski EH, Valdebran M, Amber KT. Epidermolysis bullosa acquisita: A comprehensive review. Autoimmun Rev. 2019;18(8):786-95.
  • Schmidt E, Kasperkiewicz M, Joly P. Pemphigus. Lancet. 2019; 394(10201):882-94.
  • Paolino G, Didona D, Magliulo G, Iannella G, Didona B, Mercuri SR. Paraneoplastic pemphigus: Insight into the autoimmune pathogenesis, clinical features and therapy. Int J Mol Sci. 2017;18(12):2532.
  • Kridin K, Patel PM, Jones VA, Cordova A, Amber KT. IgA pemphigus: a systematic review. J Am Acad Dermatol. 2020;82(6):1386-92.
  • Porro AM, Caetano Lde V, Maehara Lde S, Enokihara MM. Non-classical forms of pemphigus: herpetiformis, IgA pemphigus, paraneoplastic pemphigus and IgG/IgA pemphigus. An Bras Dermatol. 2014 ;89(1):96-106.
  • Kamaguchi M, Iwata H. The diagnosis and blistering mechanisms of mucous membrane pemphigoid. Front Immunol. 2019;10:34.
  • Bolotin D, Petronic Rosic V. Dermatitis herpetiformis. Part II. Diagnosis, management, and prognosis. J Am Acad Dermatol. 2011;64(6):1027-33.
  • Porro AM, Seque CA, Ferreira MCC, Enokihara MMSES. Pemphigus vulgaris. An Bras Dermatol. 2019;94(3):264-78.
  • van Beek N, Zillikens D, Schmidt E. Diagnosis of autoimmune bullous diseases. J Dtsch Dermatol Ges. 2018;16(9):1077-91.
  • Goletz S, Zillikens D, Schmidt E. Structural proteins of the dermal-epidermal junction targeted by autoantibodies in pemphigoid diseases. Exp Dermatol. 2017;26(12):1154-62.
  • Joly P, Horvath B, Patsatsi A, Uzun S, Bech R, Beissert S. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV). J Eur Acad Dermatol Venereol. 2020;34(9):1900-13.
  • Joly P, Maho Vaillant M, Prost Squarcioni C, Hebert V, Houivet E, Calbo S. French study group on autoimmune bullous skin diseases. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet. 2017;389(10083):2031-40.
  • Feliciani C, Joly P, Jonkman MF, Zambruno G, Zillikens D, Ioannides D. Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology. Br J Dermatol. 2015;172(4):867-77.
  • Patel PM, Jones VA, Murray TN, Amber KT. A review comparing international guidelines for the management of bullous pemphi- goid, pemphigoid gestationis, mucous membrane pemphigoid, and epidermolysis bullosa acquisita. Am J Clin Dermatol. 2020;21(4):557-65.
  • Kremer N, Snast I, Cohen ES, Hodak E, Mimouni D, Lapidoth M. Rituximab and omalizumab for the treatment of bullous pemphigoid: a systematic review of the literature. Am J Clin Dermatol. 2019;20(2):209-16.
La source de données: Dialnet